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Type 1 diabetes (T1D) is a disease of insulin deficiency that results from autoimmune 
destruction of pancreatic islet beta cells. The exact cause of T1D remains unknown, 
although asymptomatic islet autoimmunity lasting from weeks to years prior to 
diagnosis raises the possibility of intervention before the onset of clinical disease. The 
number, type, and titer of islet autoantibodies are associated with long-term disease 
risk but do not cause disease and robust early predictors of individual progression to 
T1D onset remain elusive. The Environmental Determinants of Diabetes in the Young 
(TEDDY) consortium is a prospective cohort study aiming to determine genetic and 
environmental interactions causing T1D. Here, we analysed longitudinal blood 
transcriptomes of 2013 samples from 400 individuals in the TEDDY study prior to 
both T1D and islet autoimmunity. We identified and interpreted age-associated gene 
expression changes in healthy infancy and age-independent changes tracking with 
progression to both T1D and islet autoimmunity, beginning before other evidence of 
islet autoimmunity is present. We combined multivariate longitudinal data in a 
Bayesian joint model to robustly predict individual risk of T1D onset, validating the 
association of a natural killer cell signature with progression as well as the model’s 
predictive performance on an additional 356 samples from 56 subjects in the 
independent Type 1 Diabetes Prediction and Prevention (DIPP) study. Together our 
results indicate that T1D is characterised by early and longitudinal changes in gene 
expression, informing the immunopathology of disease progression and facilitating 






An autoimmune pathogenesis for T1D is indicated by strong genetic association of 
HLA and other immune variants (1) along with progressive development of 
pancreatic islet beta cell autoantibodies (IAb) (2), although metabolic, microbial, and 
dietary factors also contribute (3). Genetic risk scores can identify those at highest 
risk of developing disease (4) in whom peak onset occurs in early childhood, around 
1-2 years of age (5). Studying early events associated with T1D progression is 
challenging given the need to identify at-risk subjects and to sample before evidence 
of autoreactivity begins. Previous studies have typically been cross-sectional 
investigations of small numbers of subjects after the onset of islet autoimmunity or 
T1D. Expansions of islet antigen-reactive T cells have been documented in the blood 
of both T1D cases and healthy controls (6) whereas age-dependent changes in 
immune phenotype at diagnosis (7) have underlined the complexity of studying 
disease in the context of a developing immune system. Within the pancreas, 
longitudinal single-cell RNAseq analysis has indicated complex, dynamic changes in 
infiltrating immune cell populations (8). Although comparable study of human tissue 
is not possible, pseudotime mass cytometry of pancreatic tissue from T1D-diagnosed 
donors has illustrated an influx of cytotoxic and helper T cells associated with 
reductions in beta cell mass (9).  
Longitudinal metabolomic (10) and microbiomic (11, 12) analyses prior to onset of 
autoimmunity or T1D diagnosis have indicated marked age-dependent effects but not 
a clean association with autoimmunity or disease progression. A viral trigger for 
pancreatic autoimmunity has long been proposed (13) and has been supported by both 
early transcriptional signatures of type 1 interferon response (14) and prolonged 
enteroviral shedding (15) prior to islet autoimmunity. Enteroviruses can directly infect 
pancreatic beta cells and have been linked to a natural killer cell insulitis (16). Early 
changes in blood gene expression (17, 18) prior to islet autoimmunity are likely to be 
driven by changes in relative proportions of constituent blood cells(19), although their 
interpretation is confounded by a lack of data describing how such changes develop in 
healthy infancy. 
T1D onset occurs in the dynamic context of a maturing immune system: changes 
observed in children developing autoimmunity must be carefully related to healthy 
developmental changes to focus our attention on factors that initiate and propagate 
autoreactive responses. Recently, systems immunology studies of immune 
development during infancy have indicated early, stereotyped changes in blood cell 
and protein composition (20) and dynamic changes in the gut microbiome related to 
breastfeeding patterns, islet autoimmunity (11, 12), and onset of childhood 
inflammatory disease (21). Such high-throughput analyses create the potential for 
identification of previously unsuspected pathways associated with disease initiation 
and progression to improve understanding of disease biology and aid the building of 
predictive models to suggest targeted therapies (22).  
The TEDDY study aims to identify gene-environment interactions causing T1D in 
high-risk infants participating in serial prospective sample collection and monitoring 
every three to six months from birth to age 15 years (23). By combining genetic risk 
stratification and prospective follow-up it has been possible to collect samples and 
data from infants prior to development of both islet autoimmunity and T1D onset, 
facilitating systematic analysis of early and longitudinal changes associated with the 
later development of disease. This can facilitate both an improved understanding of 
the pathogenetic mechanism of human islet autoimmunity and early prediction of its 




autoimmunity and hence long-term risk of T1D development (2), validated predictive 
markers have not been able to report serial, individual risk over a near-term horizon 
such as is necessary to inform clinical decision making (24). 
Here, we undertook transcriptional network analysis of gene expression microarray 
data using a nested case:control cohort (25) from the TEDDY study to identify early 
longitudinal changes in whole blood gene expression in healthy infancy or tracking 
with progression to both islet autoimmunity and T1D. We also built a predictive 
model incorporating multivariate longitudinal features including gene expression and 




A dynamic landscape of whole-blood gene expression during infancy 
We analysed data from nested, matched case control cohorts (25) comprising 2013 
whole blood transcriptomes sampled longitudinally from 401 individuals, divided into 
those developing islet autoimmunity or T1D (Fig. 1A, B, fig. S1-2). We applied 
transcriptional network analysis (26) to identify groups of coexpressed genes 
(modules) based solely on patterns of transcription in the data (Fig. 1C, D, fig. S1B). 
We first constructed independent transcriptional networks for both cases and controls, 
observing closely matched coexpression patterns in each with no evidence of disease-
specific modules (fig. S1B): genes coexpressed in cases were found to be similarly 
coexpressed in the control cohort and vice versa (Fig. 1C, D). As genes in a module 
are by definition coexpressed, they can be summarised by a single profile known as 
an eigengene (27). As coexpression patterns were preserved in disease and control 
groups, we constructed a coexpression network based on all samples considered 
together (fig. S1B) and applied linear mixed modelling to whole blood modular 
eigengenes from this combined network (table S1). We found that a substantial 
proportion of modules (23/85, 27%) demonstrated significant temporal changes 
during infancy (FDR < 5%, Fig. 1E). Patterns of gene coexpression are highly 
conserved (28) and modular signatures can be interpreted by screening their 
composite genes for enrichment of well-defined gene expression signatures in 
external relational databanks and public repositories (fig. S1) (29, 30). In this way, the 
biological meaning of the identified patterns of gene coexpression can be interpreted, 
with the caveat that repositories typically include samples and data from adults rather 
than infants. We compared each age-associated module (Fig. 1E) to the largest 
compendium of cell- and tissue-specific transcriptomic signatures (ARCHS4 
repository (30)), identifying frequent modular enrichment for cell type-specific 
transcripts (17/23, 74%), upstream kinases (22/23, 96%) and transcription factors 
(22/23, 96%) (fig. S3) including progressive reductions in stem cell-specific 
transcripts (Fig. 1F) along with B cell- and neutrophil-specific transcripts and 
associated transcription factors (fig. S3).  
We also undertook ‘digital cytometry’, using a deconvolution approach comparing 
whole blood transcriptional profiles to immune cell-specific transcripts to estimate 
cell type frequencies (Fig. 1G) (31). This confirmed the association of the majority of 
modular signatures identified with the frequency of circulating immune cell 
phenotypes (Fig. 1G). Individual modular signatures correlated with multiple 
deconvoluted cell frequencies as expected, as cell percentages often vary together 
during an immune response. 
Multiple modular signatures mapped to the same cell type despite showing distinct 




proportion of circulating cell types in blood alone and likely reflect more subtle 
phenotypic differences than can currently be mapped by deconvolution or enrichment 
strategies. Together these data show marked gene expression changes during healthy 
infancy, highlighting the dynamic context in which autoimmune diseases such as T1D 
occur. 
 
Distinct disease-specific transcriptional signatures in T1D subgroups 
We next asked whether longitudinal changes in modular patterns of gene expression 
tracked with progression towards T1D onset. As children get older, they inevitably 
approach the time of disease onset. Consequently, it is necessary to ensure that the 
longitudinal changes seen in cases are not simply age-associated changes expected to 
occur in healthy children. To overcome this, we identified modular eigengenes 
correlating with time to T1D in cases and, as the study design included age-matched 
healthy samples, compared these to the longitudinal changes seen in infants who did 
not progress to disease (Fig. 1H, I). Although 35 modular signatures significantly 
correlated with T1D progression (FDR<5%), none were specific to T1D cases and all 
showed stronger association with healthy ageing in matched controls (Fig. 1I), 
highlighting the importance of placing longitudinal changes into the dynamic immune 
context of early infancy.  
 
T1D is thought to be a heterogeneous condition, however evidence supporting the 
existence of disease subgroups has proven elusive (32, 33). Those developing 
autoantibodies to insulin (IAA) show earlier and more rapid progression to both 
additional IAb and to T1D than those initially developing IAb to the other major 
pancreatic autoantigen, GAD (glutamic acid decarboxylase) (2). However, it remains 
unclear whether this observation reflects a distinct immunopathology, or simply 
autoimmunity occurring at younger age. We next stratified the T1D cohort by target 
of first appearing autoantibody, comparing modular gene expression changes in IAA-
first and GADA-first subgroups with their matched controls as before. Whereas 
disease-specific longitudinal changes were not apparent in T1D on the whole (Fig. 
1I), distinct gene expression signatures showed clear age-independent association 
with time to T1D onset in IAb subgroups (Fig. 2A, B). Amongst IAA cases, one 
dominant signature (IAAsig) showed an early increase in expression with a later 
secondary increase prior to diagnosis (Fig. 2C), a pattern not seen in most matched 
controls. The nested study design allowed for IAb seroconversion to occur in the T1D 
control group (25), provided T1D progression did not occur. Closer analysis of the 
control group demonstrated that IAAsig expression showed a similar early rise in 
seroconverting controls, falling off with advancing age where they were maintained in 
those progressing to T1D (Fig. 2C inset, IAbposT1Dneg vs. IAbnegT1Dneg). By contrast, 
seronegative controls showed no comparable rise in early IAAsig expression (Fig. 2C 
inset). In GADA cases, a group of four closely correlated signatures termed together 
as GADAsig, (Fig. 2B) showed an age-independent decrease towards T1D onset, a 
pattern absent from matched controls and occurring closer to diagnosis in contrast to 
the earlier increases in the IAAsig (Fig. 2C, D). We compared mixed models to 
ensure that observed gene expression changes were independent of additional clinical 
covariates including sex, ethnicity, and HLA risk group (table S2) alongside mode of 
birth delivery and patterns of maternal breastfeeding (fig. S4C-F). This analysis 
indicated an independent and significant association of both gene expression 
signatures and sex, but not the other variables, to the models (table S3). We therefore 





Biological interpretation of T1D-specific signatures 
We next performed enrichment analysis of both IAAsig and GADAsig (table S4) 
against relational databases (ARCHS4 (30) and DICE (34)) providing the largest and 
most granular coverage of immune cell-specific gene expression, and also correlated 
each module’s eigengene against cell subset frequencies estimated through 
deconvolution analysis (31). IAAsig genes showed strong, specific enrichment for 
natural killer (NK) cell-specific transcripts (Fig. 2E, F), transcription factors, and 
kinases (fig. S5) and correlated with deconvoluted percentage of NK cells, and to a 
lesser but still significant extent with CD4+ memory T cells (Fig. 2G). Genes 
comprising GADA-specific modules were enriched for transcripts shared by both 
blood and brain tissue but not clearly with a single cell type (Fig. 2H, I, fig. S5). 
However, comparison with deconvolved cell type frequencies indicated strongest 
associations with reduced percentage of CD4+ memory T cells and NK cells, with a 
relative increase in an activated NK phenotype (Fig. 2J). This observation suggests 
the early stages of T1D pathogenesis are associated with different immune cell 
trajectories that involve similar immune cell types, namely NK and CD4+ memory T 
cells, depending on the pattern of initial IAb seroconversion.  
 
To investigate potential means of therapeutically modulating IAAsigs and GADAsigs, 
we compared each to an integrated repository of drug response data (the 
Harmonizome (35, 36)), that links functional associations between genes and proteins 
based on collated genomic data including physical associations, knockout or 
knockdown phenotypes, and response to drug treatment. We screened IAAsig genes 
against all 352 ‘druggable’ targets (30) linked to 20883 genes and identified a single 
candidate G-protein coupled receptor (GPR171, Fig. 2K) as a potential controller of 
IAAsig genes. That is, GPR171 was not itself part of the modular signature but 
instead predicted to be functionally associated with genes comprising it. We 
confirmed NK cell -expression of the IAAsig and GPR171 at both mRNA (Fig. 2L) 
and protein abundance (Fig. 2M) and demonstrated that a specific inhibitor of its 
signalling (Inh) could attenuate both GPR171 expression and NK cytotoxicity in an in 
vitro killing assay (Fig. 2N). Together, these data demonstrate that distinct cell-
specific gene expression changes characterise progression to disease onset in 
subgroups of patients with T1D defined by their sequence of IAb seroconversion. 
 
Transcriptional signatures associated with islet autoimmunity 
Next, we asked whether specific changes in gene expression occur around the onset of 
islet autoimmunity (IAb seroconversion), rather than tracking with progression to 
disease onset (Fig. 3A). Amongst 50 modular signatures showing significant 
association with islet autoimmunity onset (Fig. 3B, C), a dominant signature 
associated with seroconversion in both subgroups. This signature (IAsig) was 
common to both GADA and IAA subgroups and, although it showed significant 
dynamic changes in matched healthy controls, there were more marked and sustained 
reductions in infants progressing to IAb seroconversion (Fig. 3D, E). Interrogation of 
this islet autoimmunity signature (table S5) revealed strong enrichment for B cell-
specific transcripts, kinases, and transcription factors (Fig. 3F). Six additional 
signatures (Fig. 3B, C) showed a weaker but still significant age-independent 
association with islet autoimmunity onset, again in both GADA and IAA subgroups. 
The second-most strongly associated signature was the same NK-enriched signature 




autoimmunity onset but showed no change over time in the control group (Fig. 3G, 
H). Together these data indicate that longitudinal changes in NK- and B cell-
associated gene expression track with progression towards the onset of islet 
autoimmunity with NK associated changes also tracking with progression to disease 
in the IAA subgroup. 
 
Validation of T1D-specific longitudinal gene expression changes 
We next sought to validate our findings in an independent cohort of IAb and T1D 
cases. The DIPP cohort (37) is a prospective, population study of incident islet 
autoimmunity and T1D with a comparable nested case:control design although with 
sampling commencing in slightly older children (18). We undertook an independent 
network transcriptomic analysis of 356 DIPP samples from 58 individuals, again 
comparing dynamic changes in modular gene expression to both islet autoimmunity 
(Fig. 3I) and T1D onset (Fig. 3J). In this smaller cohort, an NK cell-enriched 
signature (directly comparable to that identified in TEDDY, fig. S6, table S6) was the 
only gene expression pattern that showed a significant association with both IAb 
seroconversion and T1D progression which did not similarly change in matched 
controls (Fig. 3I, J). A B cell signature comparable to the IAsig seen in TEDDY (Fig. 
3G, H) was significantly associated with both clinical endpoints, but in the DIPP 
cohort showed a comparable association with sampling age. Similar to what was 
observed in the TEDDY cohort, the NK signature increased towards T1D onset with a 
later decline in matched controls who did not go on to develop disease (Fig. 3I, J). 
Together, these data confirm an independent association of an NK cell-enriched 
transcriptional signature with both IAb seroconversion and rate of progression to 
T1D, validating the finding in the larger TEDDY discovery cohort. 
 
Gene expression in early infancy associates with rate of disease progression 
We next sought to investigate whether whole blood gene expression changes in early 
infancy, prior to demonstrable evidence of islet autoimmunity, were related to later 
risk of progression towards T1D. For this ‘snapshot’ of early risk, we identified the 
earliest samples available within the case:control cohorts, comprising 288 samples 
from 288 individuals, all taken prior to seroconversion and with >85% taken within 
the first 12 months of life (Fig. 4A, B). In this cross-sectional analysis, we constructed 
a gene coexpression network and looked for evidence of association with both disease 
risk (outcome T1D+ vs T1D-) and rate of subsequent progression towards T1D. As 
longitudinal changes were not being considered, we used regression analysis to adjust 
for variable sampling age and sex. At this early timepoint four modules were 
associated with the rate of subsequent progression towards T1D (Fig. 4C, D). Both 
enrichment and deconvolution correlation analyses of these modules indicated 
specific excess of B lymphoblast and monocyte expressed transcripts respectively 
with the latter also enriched for TNF and complement pathway signalling (Fig. 4E, 
table S7, figS6H, I). These data indicate that early high expression of a TNF-enriched 
monocyte signature and early low expression of a B lymphoblast signature were 
associated with slower progression to T1D onset (Fig. 4C, D). No modular signatures 
were significantly different between T1D and healthy control groups, although the 
TNF-enriched monocyte signature that associated with protection against T1D was 
markedly higher in infants who later seroconverted without developing T1D (IA+T1D-
, Fig. 4F).  We also observed that the same pattern of monocyte/TNF associated 




months prior to diagnosis of T1D (Fig. 4G), a finding that was also validated in the 
DIPP cohort (Fig. 4H). 
 
Previous analyses have identified a type 1 interferon response signature expressed in 
at-risk children prior to antibody seroconversion and associated with previous 
respiratory infections (14). Such a signature was clearly visible in the TEDDY cohort 
(Fig. 4I) although it was not associated with risk of T1D (Fig. 4C) or rate of 
progression to T1D (Fig. 4J). However, the IFN response signature conformed to a 
pattern of transient ‘spikes’ of expression, likely following infectious triggers, most 
frequently observed in the 12 months prior to disease onset (Fig. 4J, K) and to an 
extent that exceeded those seen in age-matched control samples (Fig. 4L). 
 
Prediction of individual T1D risk using longitudinal data 
Recently, statistical learning methods have improved our ability to integrate baseline 
covariates, longitudinal data. and clinical endpoints to estimate instantaneous event 
hazards (38). Current T1D prediction methods stratify disease risk by number of IAb 
present, indicating cohort level risk over a horizon of many years, making it difficult 
to incorporate this information into treatment pathways or to enable recruitment into 
clinical trials of targeted therapy (Fig. 1B). Individual risk prediction over a short time 
horizon is necessary to guide clinical decisions and preventive therapy trials (24). We 
therefore aimed to build a predictive model that could estimate, with an indication of 
uncertainty, the near-term hazard of T1D for an individual, dynamically updating that 
prediction as additional data becomes available. We used a multivariate Bayesian 
joint model (39) to combine baseline stratification (using a Cox proportional hazards 
model) with longitudinal variables such as IAb type, status, timing, and gene 
expression, returning an event hazard with associated confidence bounds. As our 
earlier analysis of comparative mixed models had demonstrated independent 
association of both gene expression signatures and sex (table S3) with gene 
expression signatures depending on the sequence of serial IAb seroconversion, we 
incorporated these covariates into a joint model (Fig. 5A). We chose to build and test 
the performance of three distinct models in each of two clinical scenarios. Predictive 
performance (ROC AUC and prediction error) was estimated using 10-fold cross-
validation on the discovery cohort (TEDDY, Fig. 5B) and on an independent 
validation dataset (DIPP). The three models each included baseline stratification by 
sex and either (i) IAb status over time (IAb+/-), (ii) maximal IAb information (IAb 
specificity [IAA, GADA, IA-2A], timing of IAb seroconversion, sequence of IAb 
seroconversion specificity and associated interaction effects) or (iii) maximal IAb 
information along with longitudinal gene expression data (the eigenvalues of the IAA 
or GADA signatures). The two clinical scenarios tested were serial prediction over a 
fixed future horizon of 12 months using all cumulative data available at each 
timepoint (mimicking a child being followed up over time, Fig. 5C-F), and prediction 
at 1.5 years of age over a serially increasing future horizon (mimicking prediction 
with early limited data, Fig. 5C-F).  
Using islet autoimmunity status alone – the scenario most comparable to current 
methods (24) - had modest predictive accuracy in both clinical scenarios (model i, 
Fig. 5C). The inclusion of maximal IAb information (model ii) allowed for robust 
prediction in the first clinical scenario (serial prediction over a fixed horizon of 12 
months: Fig. 5D, left panel: ROC AUC>0.9, PE <10%) with only modest 
improvement by inclusion of longitudinal gene expression signatures (model iii, Fig. 




T1D prediction, it is also apparent that making predictions close to diagnosis (in this 
scenario predicting 12 months ahead) is supported by using IAb data. By contrast, and 
consistent with the importance of early gene expression measures, gene expression 
signatures supported model performance (model iii) more strongly in the second 
clinical scenario, where predictions were made early over a serially extending time 
horizon. This was particularly apparent with prediction over the first few years of life, 
when the majority of infant T1D cases occurred (Fig. 5D and E). These data show 
that, although the presence of islet autoantibodies is associated with disease risk (40), 
incorporating information on serial changes in the type, number and timing of 
seroconversion can facilitate T1D risk prediction at an individual level over a time 
horizon short enough to facilitate changes in clinical monitoring or therapeutic trials. 
Gene expression measures provided greatest support for prediction when measured 
early (up to 18 months) to predict T1D risk over a longer time horizon (up to 5 years 
in this dataset). 
 
Discussion 
Together our data describe dynamic changes in the infant blood transcriptome and 
show that patterns of islet antibody seroconversion define subgroups of T1D with 
both distinct rates of progression and distinct age-independent gene expression 
signatures associated with time to disease onset. Amongst healthy infants we observed 
extensive longitudinal changes in gene expression over the first five years of life, 
highlighting the dynamic immune context in which early islet autoimmunity develops. 
This observation reinforces the importance of taking such changes into account when 
seeking to differentiate disease-specific changes from those reflecting ‘healthy’ 
immune development. 
On taking age-associated changes into account, we observed specific, longitudinal 
changes in gene expression tracking with progression towards both islet autoimmunity 
and T1D onset. Distinct changes were associated with T1D progression in subgroups 
defined by the target of initial seroconversion. The two dominant serospecificities at 
onset of islet autoimmunity (IAA and GADA) have been proposed as distinct disease 
‘endotypes’, with the former developing earlier and showing faster progression 
towards T1D onset (41). Consistent with a distinct pathogenetic mechanism 
underpinning this stratification, we observed that distinct transcriptional signatures 
tracked with progression to T1D onset in subgroups defined by the specificity of the 
first appearing islet autoantibody (IAA or GADA). Earlier changes tracking 
progression to onset of islet autoimmunity were similar in both groups, however. We 
identified an NK cell-based signature that increased in expression with progression 
towards both islet autoimmunity and T1D in IAA-first individuals. The same 
signature was similarly seen to associate with time to islet autoimmunity but not T1D 
onset in GADA-first subjects. Association of a very similar NK cell signature was 
validated in an independent analysis of longitudinal samples from the DIPP study. 
However, further work is required to understand the mechanism underlying this 
association. NK cells have a complex relationship to autoimmunity and may function 
as either effector cells contributing to tissue damage, or as regulators of 
immunopathology(42).  Differences in NK cell phenotype have been described after 
T1D diagnosis (43) – although accompanied by many other late differences (44) - 
whereas changes in their number and phenotype have been variably linked to either 
aggressive insulitis (45) or protection from it (46) in animal models. Perhaps the most 
likely explanation for the observed association with T1D progression here is that a 




Persisting enteroviral infection has been associated with T1D progression (15) and is 
known to infect pancreatic beta cells, inducing early NK infiltration and cytolysis in 
animal models (47, 48). Our data indicate a prominent and specific role for NK cells 
in the development and progression of autoimmunity and T1D in humans, beginning 
at the earliest stages and tracking longitudinally with rate of progression rather than 
simply differentiating those who already have disease from those who do not. 
Although it is difficult to further refine the source of the NK-specific transcriptional 
signature using whole blood data, it is unlikely that it simply reflects a relative 
expansion of peripheral NK cells, as evidenced by our identification of other NK cell-
enriched modular signatures that did not associate with disease progression. Perhaps 
the most likely explanation for the observed NK association with T1D progression is 
that a viral trigger results in altered NK cell phenotype that tracks with progressive 
insulitis. Persisting enteroviral infection has been associated with T1D progression 
(15) and enteroviruses are known to infect pancreatic beta cells, inducing early NK 
infiltration and cytolysis in animal models (47, 48). An NK-predominant insulitis has 
also been observed in pancreas from diabetic organ donors with Coxsackie B4 
enteroviral infection (16) and is consistent with an autoreactive effector role for NK in 
T1D pathogenesis. However, NK cells may also function to regulate T cell-mediated 
immunity during persistent viral infection (49). A limitation of the current study is 
that, while the association of an NK transcriptional signature is validated and may be 
used for predicting progression, the mechanism linking NK cells to insulitis requires 
further investigation. 
Despite these limitations, we also demonstrate that a disease-relevant transcriptional 
signature can serve as the starting point for further mechanistic understanding and 
novel therapeutic approaches. By screening the NK-enriched T1D progression-
associated signature against collated genomic information from many sources, we 
predicted and confirmed in vitro that inhibition of a poorly characterised G-protein 
coupled receptor (GPR171, previously known for its role in controlling satiety 
signalling in the hypothalamus (50) ) was capable of suppressing NK cytolytic protein 
expression.  
We also undertook a systematic network analysis of age-independent blood 
transcription, prior to IAb emergence with the large majority of samples taken during 
the first year of life. In these earliest samples we observed reciprocal association of B 
lymphoblastic and TNF-enriched monocytic signatures that associated with the 
subsequent rate of progression to T1D. Although these signatures were not different 
between those later developing T1D and matched controls they were specifically 
increased in subjects who progressed later to islet autoimmunity without developing 
T1D (IAb+T1D-). Although it is tempting to speculate that this evidence supports a 
protective role for early inflammatory signals – such as proposed by proponents of the 
‘hygiene hypothesis’ (51) – studies in animal models have highlighted the complexity 
of altered TNF signalling with evidence for distinct roles at different disease stages 
(52, 53). However, the validated association of increased expression of this signature 
in T1D-protected individuals despite islet autoimmunity may help inform 
interventional study design (54). 
Previous hypothesis-driven analyses of early gene expression changes identified an 
increase in type 1 interferon (IFN1) signalling in pre-T1D children linked to history of 
recent infection (14). A comparable signature was apparent in the TEDDY cohort and 
showed transient elevation in ‘spikes’ consistent with response to an infectious 
stimulus (and quite different to the chronic, progressive increase seen in the NK 




preceding T1D onset compared with age matched controls but was not associated with 
the rate of progression to islet autoimmunity or T1D. This is consistent with a role for 
IFN1 signalling – and perhaps viral infections that provoke transient IFN1 elevations - 
in modifying disease progression. However, as with NK cells, evidence from animal 
models shows that IFN signalling may play either a role in promoting T cell mediated 
insulitis(55) or in protecting beta cells from NK cell mediated attack(48). 
Last, we sought to incorporate the longitudinal measurement of immune traits – both 
gene expression and IAb – into a predictive model that could provide an estimate of 
an individual’s T1D risk and the confidence of that estimate. Long-term risk of T1D 
(over the subsequent 10-15 years) can currently be informed by the extent of IAb 
seropositivity. However, for a predictive model to impact on clinical decision making 
– whether by altering the frequency of clinical review to monitor for severe 
complications such as diabetic ketoacidosis (56) or by facilitating early intervention 
studies (24) – it is necessary to obtain a robust estimate of near-term risk of T1D 
onset. We therefore sought to build a predictive model that could estimate individual 
T1D risk in two specific scenarios: either making an early prediction (at 18 months) 
over a longer horizon (5 years), or by using cumulative data to make serial predictions 
over the subsequent 12 months. To test the ability of both baseline and longitudinal 
measures to inform this prediction, we built a Bayesian joint model incorporating 
either Ab status alone, or with more extensive IAb features (serospecificity, timing, 
and interaction of IAb development) with or without gene expression signatures. We 
included stratification by sex (as this was the only other covariate demonstrating 
independent association with progression rate), but intentionally excluded HLA 
stratification (despite a demonstrated association with progression (57)) to facilitate 
extrapolation between global populations with distinct HLA distributions. This 
approach allowed direct comparison between both simple and more complex models, 
aiming to establish optimal prediction with the simplest approach requiring as few 
measurements as possible. With predictions made over a short horizon of 12 months, 
the model with extensive IAb features outperformed standard prediction using IAb 
status alone and gained little support from including gene expression data: this is 
consistent with observations that IAb are often positive within 12 months of 
diagnosis(58) and our model supported robust prediction of T1D progression in this 
scenario. However, it is an onerous task to repeatedly sample children at such an early 
age to obtain longitudinal data on timing and sequence of seroconversion specificities. 
We therefore tested a second scenario, using data only from the first 18 months and 
making predictions progressively further ahead. Predicting from this earlier timepoint 
– arguably a more feasible clinical scenario given the reduced sampling requirement – 
showed a benefit of gene expression signatures in addition to IAb measures with 
robust performance on both cross-validation and independent validation cohort 
testing.  
The current study identified extensive, longitudinal changes in the whole blood 
transcriptome occurring during both healthy infancy and progression to T1D. This 
finding has been made possible through assiduous prospective collection of samples 
by the TEDDY consortium. We show here that these changes can be both interpreted 
and used to inform prediction of T1D risk from an early age. Extensive sampling at an 
early age is facilitated by the simplicity of whole blood collection. However, this 
method also limits the biological interpretation of modular signatures identified. The 
modular signatures identified here are dominated by cell-subset specific transcripts, 
with both module enrichment and deconvolution methods in broad agreement. Each 




that signal is derived from a mixed cell population like peripheral blood, it is more 
difficult to pin down the cell-intrinsic pathways responsible for that change in gene 
expression. Improved methods for deconvolution may help to address this problem 
(59) but require robust validation against concurrently sampled cell intrinsic 
transcriptomes. Transcriptional profiling of sorted cell populations (60) or single cell 
profiling (61) methods can similarly overcome this limitation, but they inevitably 
result in sampling of a much smaller cohorts. It is clear from our analyses that 
enrichment and deconvolution approaches can be complementary. As deconvoluted 
cell subset proportions may vary together, for example increasing together during an 
inflammatory response, it is expected that a transcriptional signature may correlate 
with multiple cell subset proportions, making it harder to define the source of that 
signal through deconvolution alone. Enrichment is not similarly encumbered by this 
problem, relying instead on co-expressed features within the module itself for 
interpretation although it is inevitably constrained by the availability of external 
signatures for enrichment analysis.  
We have demonstrated and validated an association of NK cell gene expression 
signature with T1D progression. It remains to be determined whether this change 
reflects a causal contribution to T1D related immunopathology or a host response to 
an infectious trigger, or both. An answer to this fundamental question will require 
further analyses and more detailed investigation of prospective data and samples. 
 
Longitudinal measurement of gene expression patterns in infancy are dynamic but 
accounting for these changes allows identification of an age-independent NK gene 
expression signature that tracks with rate of progression to T1D. Incorporating gene 
expression signatures alongside patterns of islet autoimmunity seroconversion 
facilitates robust prediction of individual risk, validated in an independent cohort. 
This creates the potential for early monitoring of at-risk infants for T1D onset, 
facilitating the prevention of severe complications such as ketoacidosis (62), effective 
trialling of preventive therapies or the identification of targets for immunomodulation 
(63). 
 
Materials and Methods 
Study design 
TEDDY and nested case:control study design 
Enrolment to the TEDDY study and design of the nested case-control biomarker 
discovery study is described in full elsewhere (25) and summarised here (fig. S2). In 
brief, the TEDDY study enrolled children <4.5 months of age from December 2004 to 
July 2010 through new-born screening for high-risk HLA-DR-DQ genotypes at six 
international centres (3 US, 3 EU). Written consent was obtained from primary carers 
for all participants, ethical approval was obtained from local institutional review 
boards and the study is monitored by an external evaluation committee formed by the 
National Institutes of Health. Blood samples were prospectively collected from 3 
months of age, continuing at 3 monthly intervals until age 4, then every 6 months 
until age 15 unless seroconversion to persistent islet autoimmunity has occurred when 
they continued every 3 months until age 15. The primary endpoints of the TEDDY 
study are: (i) the appearance of persistent, confirmed islet autoimmunity, defined as 
the presence of one confirmed islet autoantibody (IAA, GAD65A or IA-2A) on at 
least two consecutive samples. islet autoimmunity result confirmation was obtained 
through reciprocal sample testing at two laboratories with the date of persistent 




subsequently shown to be persistent, and (ii) the clinical appearance of T1D, as 
defined by the American Diabetes Association diagnostic criteria (64).  
Samples used for genomic analysis within the nested case:control study design used 
here were identified by risk set sampling in which islet autoimmunity and T1D 
controls were randomly selected from individuals who were free of the relevant event 
within 45 days of the case’s event time using best available sample matching for 
clinical centre, sex, family history of T1D, and age (figS7). This identified two 
separate nested, matched cohorts each relating to one of the primary endpoints of the 
TEDDY study, namely T1D onset, and onset of islet autoimmunity (Fig. 1A, figure 
S2, table S2)(25).  
The current study was designed to identify transcriptional coexpression networks in 
longitudinal whole blood transcriptomes in the TEDDY nested case:control study. 
Independent transcriptional networks were identified in and compared between 
subjects progressing to T1D or islet autoimmunity and age-matched controls (Fig S1) 
Eigengenes summarising coexpressed gene modules were then generated and 
modelled against the principal endpoints of the TEDDY study, namely the onset of 
islet autoimmunity and diagnosis of T1D. Association of early coexpression networks 
(measured in the earliest sampling timepoint for each individual) with later 
progression to either T1D or islet autoimmunity was also undertaken. For validation 
purposes, independent network analysis was undertaken of whole blood gene 
expression data from the publicly-available DIPP cohort (GSE30211). 
 
RNA extraction and microarray hybridization 
The TEDDY study collected 2.5 ml of peripheral blood to extract total RNA from 
enrolled children. Total RNA was extracted using a high throughput 96-well format 
extraction protocol using magnetic (MagMax) beads technology at the TEDDY RNA 
Laboratory, Jinfiniti Biosciences. Purified RNA (200 ng) was further used for cRNA 
amplification and labeling with biotin using Target Amp cDNA synthesis kit 
(Epicenter). Approximately 750ng of labeled cRNA was hybridized to the Illumina 
HumanHT-12 Expression BeadChips as per manufacturer’s instructions. The 
HumanHT-12 Expression BeadChip provides coverage for more than 47,000 
transcripts and known splice variants across the human transcriptome. After 
hybridization, arrays were washed, stained with Cy3-conjugated streptavidin, and 
scanned. 
 
Microarray data preprocessing and normalization  
The beadarray and lumi Bioconductor packages were used for preprocessing 
microarray data including image analysis, quality control, variance stabilization 
transformation, normalization and gene annotation. The MedianBackground method 
was used for local background correction. In addition, the BeadArray subversion of 
harshlight (BASH) method was used for beads artifact detection, which takes local 
spatial information into account when determining outliers. Each probe is replicated a 
varying number of times on each array; the summarization procedure produces a bead 
summary data in the form of a single signal intensity value for each probe. Illumina’s 
default outlier function and modified mean and standard deviation were used to obtain 
a bead summary data. Variance-stabilizing transformation (vst) (65) and robust spline 
normalization (RSN) (66) method which combines the features of quantile and loess 
normalization were used for generating between-array normalization data. Quality 
control was performed by excluding arrays from further analysis with the corrupted 




that were masked by the BASH method (67), low mean or median number of beads 
used to create the summary values for each probe on each array after outliers removal, 
low proportion of detected probes, low percentage of housekeeping genes expressed 
above the background level of the array, gender discrepancies using massiR package 
and poor pairwise array correlations. Transcriptional data from the DIPP cohort 
(GSE302011) was accessed from the NCBI-GEO repository using the GEOquery 
package from bioconductor in RStudio (version 3.5.1).  
 
Transcriptomic QC and batch correction. 
All the nested case-control pairs for the longitudinal transcriptome data were assigned 
to the same batch to constrain batchwise variation. In total, 2013 TEDDY samples 
were processed in 31 batches with a median batch size of 74 samples per batch 
(range: 18 to 86 samples per batch). In addition, two external QC samples (Donor 1 
and Donor 2) were included in each batch to estimation of batch-to-batch variations. 
The MedianBackground method was used for local background correction. In 
addition, the BeadArray subversion of harshlight (BASH) method was used for beads 
artifact detection(67), which takes local spatial information into account when 
determining outliers. The first two principal components of the gene expression data 
before and after normalization, respectively are shown in figS8. The mean pairwise 
Pearson correlation coefficients after normalization were 0.97 (standard deviation 
(SD) = 0.04) for Donor 1 and 0.99 (SD = 0.01) for Donor 2. 
 
Statistical analysis 
Transcriptional network analysis 
After data processing and quality control, 2013 samples from 401 individuals were 
included in the current analysis, representing 1698 samples from 342 individuals in 
the islet autoimmunity case:control study and 795 samples from 125 individuals in the 
T1D case:control study (fig. S2). For islet autoimmunity analyses, samples taken prior 
to onset of islet autoimmunity from both T1D and IA case:control cohorts were 
included along with their respective matched controls, stratified by the specificity of 
the first seroconversion as indicated. Transcriptional data was variance filtered (using 
the inflection point of cumulative median absolute deviation distribution) with data 
from 15,000 probes included in modular network analyses. The weighted gene 
coexpression networks (WGCNA) bioconductor package in Rstudio (version 3.5.1) 
was used to identify networks of co-expressed transcripts with scaled eigenvalues 
taken forward for lmm modelling. Scale-free topology was confirmed and a soft 
thresholding power selected by serial modelling of mean connectivity and adjacency 
functions. The network was constructed with a specified minimum module size of 
n=30 and medium sensitivity to cluster splitting (deepsplit =2). Independent networks 
were generated on cases and controls with comparison of network structure 
undertaken using WGCNA in Rstudio applying a composite preservation statistic as 
described(68) (fig. S1B). Modular structure in selected subgroups was visualised 
using tSNE plots using the Rtsne package from CRAN. As equivalent modular 
structure was identified in cases and controls, network analysis was repeated using the 
full cohort of 2013 samples to identify ‘universal’ modular eigengenes applicable to 
the entire cohort (rather than define them separately, fig. S1B).  
For the DIPP cohort, the public dataset (GSE30211) was downloaded from GEO into 
R followed by filtering to retain unique genes, selecting those with the largest IQR per 




the TEDDY dataset to identify a matching set of n=9313 unique features that were 
used for modular network analyses as for the TEDDY dataset. 
 
Longitudinal modelling  
Longitudinal changes in gene expression were modelled by applying linear mixed 
modelling (lmm) to scaled modular eigenvalues using the lme4 package from CRAN 
in Rstudio (version 3.5.1). To identify changes in gene expression of cases that were 
not seen in matched controls, models were fitted for each modular eigenvector against 
either time to event (for cases, T1D diagnosis or islet autoimmunity onset) or to 
chronological age (matched controls) and the observed fit compared between cases 
and matched controls. Significance of effects was determined using a likelihood ratio 
test against a null model in the absence of that effect. This was repeated for additional 
covariates to test their independent association with progression rate including HLA 
subgroup, ethnicity and sex. For effects deemed significant (FDR<5%), specificity of 
association was determined by comparing observed significance in cases to that in 
controls in the form of a ratio of FDR values (FDRT1D/IA:FDRcontrol). lmm were fitted 
including fixed terms (modular eigengene values and sex) and both random intercept 
and random slope terms for individuals. All identified modular signatures were 
iteratively tested with the extracted significance corrected for multiple testing using 
the Benjamini-Hochberg false discovery rate (FDR) method with a threshold for 
significance set at FDR 5%. Where indicated, for modular signatures of interest, 
modelling was repeated incorporating a natural cubic spline, implemented using the 
splines package in RStudio (version 3.5.1). Case:control lmm FDR ratios were 
visualised as radarcharts including all modules significantly associated with time to 
event, using the package radarchart from CRAN in Rstudio (version 3.5.1). Individual 
fits from lmm models were visualised using the ggplot2, sme and effects packages 
from CRAN in Rstudio (version 3.5.1). 
 
Early and pre-T1D cohorts 
For the TEDDY cohort, earliest available samples were identified from each 
individual and these were filtered for those obtained prior to IAb seroconversion 
(TEDDY preAb cohort, Fig4A). For the peri-T1D cohort, individuals were identified 
from whom a sample was taken within 365 days of diagnosis (serial IFN analysis) or 
the sample closest to diagnosis used (periT1D). The closest matched sample from the 
paired, matched control subject was used for comparative purposes. Gene expression 
modular signatures in these cross-sectional analyses were adjusted for sampling age, 
taking the residuals of a linear model including the relevant eigenvector and sampling 
age.  
 
Module enrichment analysis 
Module interpretation was performed using enrichment analysis against public 
repositories of defined transcriptional signatures as described in the text. Genes 
comprising selected modules were compared to reference signature repositories as 
indicated including ARCHS4, DICE and GO with a corrected Fishers exact test 
computed using Enrichr and visualised as the –log10 transformed adjusted value in a 
radar chart. Deconvolution analysis was undertaken using the CIBERSORT method 
against the LM22 dataset (31) with imputed cell proportions being correlated against 
module-specific eigenvectors. GPR171 was identified through a systematic screen 
against a relational database(36)) linking candidate ‘druggable’ targets (35) to 




were screened against the existing IDG library in the ARCHS4 dataset comprising 
352 ‘druggable’ targets linked to 20883 genes. All targets showing any overlap with 
T1D signature genes were included in the radar plot visualisation (Fig2I) with only 
GPR171 achieving significant overlap. 
 
NK cell analysis 
Primary human NK cells obtained from healthy volunteers and stained with an excess 
of recombinantly engineered FcR-defective antibodies (CD3 clone REA641 and 
CD56 clone REA196, Miltenyi Biosciences) to avoid pre-activation. Flow sorting of 
NK cells (CD3-CD56+) was performed using an AriaIII sorter (BD) in the Cambridge 
BRC flow phenotyping hub. Purified NK cells were cultured for 48h in complete 
RPMI-1640 in the presence of target K562 cells and either a GPR171 inhibitor 
(MS21570, Tocris biotechne) or vehicle (PBS) and stained with an excess of 
antibodies against GPR171 (polyclonal rabbit anti-human GPR171, Abcam), CD71 
(clone CY1G4, Biolegend) and Granzyme B (GZMB, clone GB11, Biolegend). 
 
Bayesian joint modelling 
For prediction we sought a method that could incorporate both baseline risk 
stratification and multiple longitudinal covariates to provide an estimate of event 
hazard with associated uncertainty. Joint models applied to longitudinal and survival 
data allow modelling of the error-free biomarker trajectories and disease process 
simultaneously and have several advantages over similar alternatives. Joint models 
have been shown to provide unbiased estimates of hazard ratios, unlike models using 
time-dependent covariates with increased performance compared to either baseline-
only or time-dependent Cox models (39, 69). Joint modelling (jm) was performed 
using the mvjmbayes, jmbayes and coxph packages (70) from Bioconductor and 
CRAN in RStudio (version 3.5.1) to estimate the probability of getting disease at a 
given point in time given the data available. Let 𝑆(𝑡) denote the survival function, 
which we define to be 𝑃𝑟'𝑇!∗ > 𝑡*, where 𝑇!∗ is the true time of getting disease for the 
𝑗th patient. 𝑆(𝑡) is estimated using the hazard function ℎ(𝑡), the instantaneous risk of 
getting disease 
ℎ(𝑡) 	= 		 lim
#$→&
𝑃𝑟(𝑡 ≤ 𝑇!∗ < 	𝑡 + 𝛿𝑡|	𝑇!∗ 	≥ 𝑡)
𝛿𝑡 ∈ [0,∞) 
Whereas standard approaches to survival analysis model and estimate the hazard 
function given the survival data at hand, Bayesian joint models allow hazard function 
estimation using both baseline covariates and longitudinal data in a proportional hazard 
model, using the predicted value from the lmm in the hazard model. This at once aims 
to reduce noise inherent in sparse biological data while not relying on assumptions that 
observations remain unchanged between measurements. The Bayesian methodology to 
compute the parameters allows for uncertainty estimates on predictions, achieved 
through Monte Carlo Markov chain sampling. We used the JMbayes package (70)  from 
CRAN in RStudio (version 3.5.1). 
The complete model including all covariates considered is given below: 
h'(t)  =  h&(t) exp{ γ𝑆𝑒𝑥' + α((𝑡)𝑚𝑖𝑎𝑎_𝑠𝑖𝑔) + α*(𝑡)𝑔𝑎𝑑_𝑠𝑖𝑔′)
+ α+(𝑡)𝑚𝑖𝑎𝑎_𝑎𝑏) + α,(𝑡)𝑔𝑎𝑑_𝑎𝑏) + 𝛼,(𝑡)𝑖𝑎2𝑎_𝑎𝑏)
+ α-[𝑚𝑖𝑎𝑎_𝑠𝑖𝑔) ×𝑚𝑖𝑎𝑎_𝑎𝑏)] + α.[𝑔𝑎𝑑_𝑠𝑖𝑔′) × 𝑔𝑎𝑑_𝑎𝑏)]
+ α/[𝑚𝑖𝑎𝑎_𝑎𝑏) × 𝑔𝑎𝑑_𝑎𝑏)] + α0[𝑔𝑎𝑑_𝑎𝑏) × 𝑖𝑎2𝑎_𝑎𝑏)]





Not all covariates were included in all model scenarios as an underlying goal was a 
sparse model incorporating covariates that can be measured in a simple, robust and 
cost-effective manner and which are likely to withstand later extension of the model 
into additional populations. Covariates used were factors that are known or suspected 
to correlate with progression to disease onset (IA) or progression (T1D diagnosis) and 
included whole blood transcriptional signatures and serial IAb data with time-varying 
effects (the hazard ratio was allowed to vary with time) and interaction effects 
between covariates (the type, number and sequence of IAb seroconversion was 
accounted for). Sex is included in our model as it has shown to correlate with T1D 
progression (71) (table S3) and is simple to obtain. HLA risk category is collected in 
the TEDDY study but was excluded to facilitate extension of the model between 
populations and ethnicities and because HLA risk groups also did not contribute to 
model performance on testing in the TEDDY discovery cohort (table S3). 
Longitudinal data was fitted with a natural cubic spline-fitted lmm from the JMbayes 
library using the mvglmer function and survival predictions were made using survFitJM 
function. The input features to predict longitudinal outcome include the natural spline 
with 3 degrees of freedom fitted to time. 
 
Predictive model performance estimates 
When building any predictive model, it is imperative to balance predictive 
performance against the risk of ‘overfitting’, whereby the model performs well on a 
training dataset but fails to predict on unseen data. Predictive performance was first 
estimated using 10-fold cross-validation on the TEDDY discovery dataset. 
Application in a clinical context was simulated by first making predictions on data 
collected up to 1 year of age, then serially increasing the amount of data available in 
steps of 0.15 years (mimicking clinical follow up), making disease predictions at each 
step over a constant time horizon of 1 year ahead. Model performance was evaluated 
using metrics addressing two key parameters, again using the JMbayes package: 
model discrimination (how well the model differentiates between individuals who 
do/do not reach an endpoint), and model calibration (how well the model predicts the 
observed data).  
For discrimination, area under the receiver operator characteristic curve (AUC ROC) 
was selected to reflect both sensitivity and specificity of predictive accuracy. For 
calibration, prediction error (PE) was used as defined below. Each metric was applied 
to both cross-validated performance estimates on the discovery TEDDY cohort and 
following application of a ‘fixed’, optimal model from the discovery set to the 
independent validation DIPP cohort (which played no part in model training).  
 
AUC is defined for a prediction horizon of Δ𝑡 as follows 
𝐴𝑈𝐶(𝑡, Δ𝑡)
= 𝑃𝑟Z π!(𝑡 + Δ𝑡|𝑡) < π!!(𝑡 + Δ𝑡|𝑡) ∣∣ {𝑇!∗ ∈ (𝑡, 𝑡 + Δ𝑡]} ∩ {𝑇!!
∗ > 𝑡 + Δ𝑡} ^ 
where π!(𝑢|𝑡) is the probability that patient 𝑗 will survive up to time 𝑢 given they are 
alive at time 𝑡 and 𝑇!∗ is the true event time (T1D onset or IAb seroconversion). 
Prediction error is defined as the expected loss given the difference between the 
predicted 𝑁)(𝑢) and the true value π!(𝑢|𝑡) as given below: 
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Figure 1. Dynamic changes in the infant blood transcriptome. 
(A, B) Schematic illustration of the (A) TEDDY cohort (B) sampling from birth, 
through IAb seroconversion to T1D diagnosis illustrating population-level risFk of 




add up to the total. (C) tSNE plot illustrating the dissimilarity matrix of gene 
coexpression networks in T1D (left) and matched controls (right). Each dot represents 
a distinct gene (n=15000). Genes in both plots are coloured by modular assignment in 
the T1D coexpression network. (D) Scatterplot showing strength of T1D module 
preservation (y axis, Zsummary score) in matched control data (red dashed line = strong 
preservation threshold, Zsummary = 10). (E) Line and scatterplots showing lmm effects 
(red, +/- 95% confidence interval [CI]) and gene expression eigenvalues (black dots) 
for 23 modular eigengenes showing significant (FDR<5%) age association in infancy. 
Colors are matched to Fig. 1 C-E. (F) Example module enrichment: line and 
scatterplot (left) showing lmm effects (red line, +/- 95% CI) for the ‘yellow’ module 
alongside radar plot (right) showing module enrichment (radial axis, -log10FDR) for 
cell type specific transcripts (G) Clustered heatmap illustrating significance (-
log10FDR) of correlation (Pearson) of deconvolved cell subset proportions (y axis) 
against modular eigengene values (x axis). (H) Schematic line and scatterplot 
illustrating the use of lmm to compare modular gene expression signatures in matched 
cases and controls. (I) Radar plots showing all modules (arranged around plot 
circumference) associated with time to T1D onset (FDR<5%, left), association of the 
same modules with sampling age in matched controls (centre) and the ratio of 
observed significance in each (FDRT1D:FDRcontrol, right). For radar plots, radial 
distance from the centre = -log10FDR, red line = threshold FDR <5%.  
 
Figure 2. Age-independent changes in gene expression accompany T1D 
progression in subgroups defined by first IAb specificity. 
(A, B) Radar plots showing age-corrected associations (lmm FDRT1D:FDRcontrol) of all 
module eigengenes (shown around plot circumference) with time to T1D onset in 
IAA-first (A) and GADA-first (B) cases. Disease specificity indicated by a 
T1D:control significance ratio >1 (-log10FDR) = red line. (C, D) Line plots showing 
individual and summary (inset) effects of natural cubic spline-fitted lmm (+/-95%CI) 
fitted to IAAsig (C) or GADAsig (D) eigenvalues in cases (left) and matched controls 
(right). (E, F) Radar plot (E) and barplot (F) showing IAA module enrichment for cell 
type specific transcripts compared to ARCHS4 (E) and DICE (F) relational databanks. 
(G) Volcano plot (left) and line plots (right) showing all (left) and selected (right) 
correlations (Pearson) of IAAsig eigengenes against deconvoluted cell proportions. 
Significance threshold (FDR<5%) = red dashed line. 
(H-J) Radar plot (H) and barplot (I) showing IAA module enrichment for cell type 
specific transcripts compared to ARCHS4 (H) and DICE (I) relational databanks. (J) 
Volcano plot (left) and line plots (right) showing all (left) and selected (right) 
correlations (Pearson) of GADAsig eigengenes against deconvoluted cell proportions. 
Significance threshold (FDR<5%) = red dashed line. For barplots (F, I) TPM = 
transcripts per million reads; expression (mean +/- sem) of IAAsig (F) and GADAsig 
(I) per cell type is shown. (K) Radar plot showing enrichment (-log10FDR) of IAAsig 
genes against 352 ‘druggable’ targets linked to 20883 genes from the IDG repository. 
Drug targets showing any overlap with IAAsig genes are included around the radar 
plot circumference. (L) Barplot (mean +/-sem, n=3-12 per group) showing IAAsig 
eigengene expression and (M) representative histograms showing GPR171 surface 
protein expression in circulating immune cell subsets (GSE22886). (N) 
Representative contour plot (upper panel) and scatterplot (lower panel) showing 
GPR171 surface protein expression (y axis, log10 MFI) and Granzyme B (GZMB) 




with K562 target cells along with vehicle (left) or a titrated dose range of specific 
GPR171 inhibitor (Inh; right). * =P<0.05, MFI = median fluorescence index. 
 
Figure 3. Age-independent changes in longitudinal gene expression accompany 
islet autoimmunity. 
(A) Schematic line and scatterplot illustrating the use of a lmm to compare modular 
gene expression signatures in matched islet autoimmunity cases and healthy controls. 
(B, C) Radar plots showing age-independent associations (FDRIA:FDRcontrol) of all 
gene expression modules significantly associated (FDR<5%) with time to islet 
autoimmunity onset in either IAA-first (B) or GADA-first (C) cases. Disease 
specificity indicated by a T1D:control significance ratio >1 (-log10FDR) = red line. 
(D) Line plots showing individual and summary (inset) effects of a natural cubic 
spline-fitted lmm (+/-95% CI) fitted to IAsig eigenvalues in IAA-first individuals 
(left, n= 82, vs time to islet autoimmunity) and matched controls (right, n= 63, vs 
age). (E) Line plots showing individual and summary (inset) effects of a natural cubic 
spline-fitted lmm (+/-95% CI) fitted to IAsig eigenvalues in GADA-first cases (left, 
n=54, v time to islet autiommunity) and matched controls (right, n=49, v age). (F) 
Radar plots showing IAsig module enrichment for cell type-specific transcripts, 
kinase targets, and transcription factor targets from the ARCHS4 dataset and barplot 
(right) showing cell specific expression of IAsig genes in the DICE dataset. TPM = 
transcripts per million reads, with expression (mean +/- sem) per cell type shown. (G) 
Line plots showing individual and summary (inset) effects of natural cubic spline-
fitted lmm (+/-95% CI) fitted to the NK cell-enriched module eigenvalues (from Fig 
2B) in IAA first cases (left, n=82, vs time to islet autoimmunity) and matched 
controls (right, n=63, vs age). (H) Line plots showing individual and summary (inset) 
effects of natural cubic spline-fitted lmm (+/-95% CI) fitted to the NK cell-enriched 
module eigenvalues (from Fig 2B) in GADA first cases (left, n=54, v time to islet 
autoimmunity) and matched controls (right, n=49, v age) (I, J) Line plots showing 
individual and summary (inset) effects of natural cubic spline-fitted lmm (+/-95% CI) 
fitted to the DIPP NK module in IApos cases (I, left, n=26, vs time to islet 
autoimmunity) and matched IAneg controls (I, right, n=32, vs sampling age) and in 
T1D cases (J, left, n=24 vs time to T1D) and matched controls (J, right, n=34, vs 
sampling age). For radar plots (F, J) radial distance = –log10FDR with threshold FDR 
(5%) in red.  
 
Figure 4. Pre-seroconversion gene expression changes associate with rate of T1D 
progression. 
(A) Schematic illustration and (B) density plot showing age distribution of earliest 
pre-seroconversion samples taken in the TEDDY transcriptomic study (TEDDY 
preAb). ‘Outcome’ indicates later progression rather than state at time of sampling. 
(C) Volcano plot showing correlation of all network modules (x axis, r) against 
adjusted significance (-log10FDR, y-axis). (D) Scatterplot illustrating inverse 
correlation of B lymphoblast (orange) and monocyte (black) modular signatures and 
their association with rate of T1D progression. (E) Radar plots illustrating enrichment 
of the orange, blue (upper), black and pink (lower) modules against the human cell 
atlas (left) and hallmark signature sets (right). Radial axis = -log10FDR, red line = 
significance threshold FDR (5%). (F) Scatterplot illustrating expression (mean+/- 
sem) of black, pink, orange, blue, and IFN response signatures by outcome group in 
the TEDDY preAb cohort, * = Mann Whitney P<0.05. Outcome group reflects final 




corrected eigengene expression of the ‘black’ monocyte/TNF-enriched signature in 
peri-T1D samples from TEDDY (n=54 samples within 12 months prior to diagnosis). 
(H) Scatterplot showing age-corrected eigengene expression of the ‘black’ 
monocyte/TNF-enriched signature in peri-T1D samples from the DIPP cohort (n=18 
samples within 3 months prior to diagnosis) and their matched controls (n=18). (I) 
Radar plot showing modular enrichment for interferon (IFN) response transcripts. (J) 
Scatter and line plots showing lmm summary of longitudinal type1 IFN module 
expression (red line, +/- 95% CI shaded) in pre-T1D children (right, n=62) and 
matched controls (left, n=62). (K) Scatter and line plot illustrating ‘spikes’ of type 1 
IFN response module and (L) age-matched peak expression in pre-T1D (red, n=57) 
and age-matched control samples (black, n=57) in the 12 months preceding T1D 
onset.  
 
Figure 5. Validated prediction of T1D hazard in at-risk infants. 
(A) Schematic of multivariate Bayesian joint model data input (top), model building 
(middle) and model performance assessment (bottom). (B) Illustration of cross-
validation method employed on discovery TEDDY cohort. (C-F) Line and scatterplots 
showing predictive accuracy of models applied to each of two clinical scenarios 
(schematically illustrated above plots in red). Left, serial prediction over future 12-
month horizon using cumulative data; right, serial prediction over extended future 
horizon using fixed data. (C) Model i incorporating IAb status (IAb+/-) only. (D) 
model ii incorporating longitudinal IAb type, status, timing and interaction effects. (E) 
model iii incorporating model ii plus IAAsig/GADAsig and interaction effects. 
Predictive accuracy (AUC ROC) determined through 10-fold cross-validation on the 
discovery TEDDY dataset as illustrated in (B). (F) Predictive accuracy (AUC ROC) 
of independent validation of model iii on the DIPP dataset (G, H) Representative line 
and scatterplots illustrating serial prediction of individual T1D risk for a T1D case (G) 
and matched control (H) with predictions every 6 months, made over a horizon of 1 
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(A) Graphical abstract and analysis overview. (A) Graphical abstract illustrating the stages of 
the current analysis. (Top) Prospective sample collection in the TEDDY study, with samples 
taken every 3-6 months towards IA, T1D or neither in at risk children. (Second from top) 
Coexpression network modelling of peripheral whole blood samples to identify modules of 
coexpressed genes and comparative preservation in different states. (Middle) Longitudinal 
mixed modelling of summary eigenvalues from each coexpression module to identify age-
associated changes in infancy and disease-specific changes relative to either T1D 
progression or IA onset. (Second from bottom) Biological interpretation of gene 
coexpression modules, identifying enrichment of external cell, transcription factor, kinase 
and drug response signatures within disease-specific coexpression modules. (Bottom) 
Building a predictive model using a combination of baseline (sex) and longitudinal (IAb, gene 
expression) covariates to facilitate dynamic, individual risk prediction over a near-term 
horizon. (B) Schematic illustration of the network coexpression analysis workflow in the 
TEDDY cohort. Network analysis was performed on T1D and matched control sets 
independently (left) with formal comparison indicating comparable modular structure in 
each (heatmap). A combined network was therefore used to identify modular eigengenes of 
coexpressed genes (‘combined’). Comparison of linear mixed models incorporating 
longitudinal changes in eigengene signatures in disease (T1D or islet autoimmunity) 
compared to age-matched controls facilitated identification of disease-specific changes. 







Supplementary Figure 2 
Schematic illustration of the nested case:control transcriptomic study established within 
TEDDY. Further description available in Ref #14. Note that IAb+ samples may appear in both 
case:control cohorts and some T1D cases had either none (IAb-) or multiple (IAA+GADA+) IAb 




Figure S3. Age-associated module enrichment. (A-C) Histogram plots showing maximal 
enrichment (x-axis, -log10FDR) of all gene expression modules associated with age in 
healthy infancy (colored blocks) for cell/tissue-specific transcripts (A), transcription factor 
(TF) targets (B) and kinase targets (C). In each case the most significant enrichment is shown 
along with its associated significance. Note that tissue-specific transcripts are included in 
the relational database, consequently ‘kidney’ expression will include infiltrating immune 






Figure S4. Sex and breast-feeding associations of modular expression changes. (A) Line and 
scatterplot showing longitudinal changes in expression of the single gene expression module 
associated with sex (B, top left) along with linear mixed model effects (red line, +/- 95% CI). 
(B) Radar plots showing significance (-log10FDR, radial axis) of association between gene 
expression modular eigengenes and sex (top left), enrichment for kinases (top right), 
transcription factor (TF) targets (bottom left) and cell/tissue-specific transcripts (bottom 
right) in the ARCHS4 repository. (C) Radar plot showing significance (likelihood ratio test, -
log10FDR, radial axis) of association between modular eigengene signatures and delivery 
mode (spontaneous vaginal delivery (SVD) v other, including caesarean section or 
instrumental delivery). (D) Density plot showing bimodal distribution of time to stopping 
exclusive breastfeeding in the full cohort (n=401 individuals). Red line indicates a 6-week 
threshold defining subgroups considered in panels E, F. (E, F) Model effects plots (+/-95% CI) 
summarising longitudinal expression of IAAsig (E, green) and GADAsig (F, black) for 
individuals with <6 weeks (E, F left) and > 6 weeks exclusive breastfeeding (E, F right). P = 







Figure S5. IAA and GADA signature enrichment. Radarplots showing enrichment of the 
TEDDY IAA and GADA signatures against the ARCHS4 (A, B) databank for cell types (top left), 
kinases (top right), transcription factors (bottom left) and predicted drug targets (bottom 
right) and against Gene Ontology annotation (C, D) for biological process (GOBP), cellular 
component (GOCC) and molecular function (GOMF) categories. Radial distance on each 
radar plot corresponds to significance of enrichment. The most enriched feature in each 




Figure S6. DIPP module enrichment. (A – D) Radar plots showing enrichment of the DIPP NK 
module (Fig. 3 J, K, n=87 probes) compared to the ARCHS4 repository of cell-type specific 
transcripts (A), kinases (B), transcription factors (C) and potential drug targets (D) as shown 
for the TEDDY NK signature in Fig. 2E. Radial distance from the centre = -log10adjustedP, red 
line = threshold FDR5%. (E) Venn diagram showing the overlap of genes included in the 
TEDDY NK (n=75) and DIPP NK (n=87) signatures, P = hypergeometric test. (F-G) Line plots 
showing individual effects of natural cubic spline-fitted linear mixed model for a B cell 
signature against time to IA seroconversion (F, left, n=183 samples from n=27 subjects) or 
age in controls (F, right, n=173 samples from n=31 subjects) and time to T1D onset (G, left 
,n=122 samples from n=22 subjects) or age in controls (G, right, n=189 samples from n=34 
subjects). (H, I) Barplots illustrating expression of each of the orange, blue, black and pink 
modular signatures against immune cell types represented in the DICE relational database. 




FigS7: Transcriptomic QC and batch correction. 
A. First two principal components of the gene expression data before normalization.  
 
B: First two principal components of the gene expression data after normalization.  
 
 
 
 
 
